KDR and non-small cell lung carcinoma: Several clinical trials combining the anti-VEGFR-2 antibody, ramucirumab, and PD1 or PD-L1 antibodies are ongoing in several indications, including non-small-cell lung cancer, recurrent/metastatic head and neck squamous cell carcinoma, and mesothelioma (NCT03904108, NCT03650764, NCT03502746), and early indications suggest the results of this combination will be promising.